Role of rivaroxaban in the prevention of atherosclerotic events-Reference-Cited by-同舟云学术

Role of rivaroxaban in the prevention of atherosclerotic events

Published:2019-07-09 Issue:8 Volume:12 Page:771-780
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Sanmartín Marcelo¹,Bellmunt Sergi²,Cosín-Sales Juan³,García-Moll Xavier⁴,Riera-Mestre Antoni⁵,Almendro-Delia Manuel⁶,Hernández José Luis⁷,Lozano Francisco⁸,Mazón Pilar⁹,Suarez Fernández Carmen¹⁰

Affiliation:

1. Cardiology Department, Hospital Ramón y Cajal, Madrid, Spain

2. Vascular Surgery Department, Hospital General Vall d´Hebron, Barcelona, Spain

3. Cardiology Department, Hospital Arnau de Vilanova, Valencia, Spain

4. Cardiology Department, Hospital Sant Pau, Barcelona, Spain

5. Internal Medicine Department, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, Barcelona, Spain

6. Cardiology Department, Hospital Virgen Macarena, Sevilla, Spain

7. Internal Medicine Department, Hospital Marqués de Valdecilla-IDIVAL, Universidad de Cantabria, Santander, Spain

8. Department of Surgery, Hospital Clinico de Salamanca, Salamanca, Spain

9. Cardiology Department, Hospital Clinico Universitario de Santiago de Compostela, CIBERCV, Santiago de Compostela, Spain

10. Internal Medicine Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain

Funder

Bayer Hispania

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2019.1637732

Reference51 articles.

1. Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association

2. Association of Temporal Trends in Risk Factors and Treatment Uptake With Coronary Heart Disease Mortality, 1994-2005

3. 2013 ESC guidelines on the management of stable coronary artery disease

4. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis

5. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase—Bridging Basic Research to Clinical Findings;Biomolecules;2024-08-07

2. Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics;Current Pharmaceutical Design;2024-06

3. Pleiotrope Effekte von NOAC mit Fokus auf Edoxaban – wissenschaftliche und potenzielle klinische Implikationen;Herzschrittmachertherapie + Elektrophysiologie;2023-05-04

4. The protective effect of rivaroxaban with or without aspirin on inflammation, oxidative stress, and platelet reactivity in isoproterenol-induced cardiac injury in rats;Naunyn-Schmiedeberg's Archives of Pharmacology;2022-11-05

5. Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials;International Journal of General Medicine;2022-09